Verdiva Bio

Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable treatments for obesity and cardiometabolic disorders.

Its pipeline centres on rationally engineered peptide candidates acting on GLP-1 and amylin receptors, advanced through a proprietary oral absorption technology designed to enable once-weekly dosing.

The lead programme is in Phase 2b clinical development, with earlier-stage amylin candidates in preclinical development for monotherapy and combination use.